Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II pilot study of pomalidomide + oral dexamethasone + very low-dose cyclophosphamide in refractory multiple myeloma
2015-004530-94Phase 2Terminated
- Sponsor
- Fundación para la Investigación Biomédica de Córdoba
- Start
- Feb 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pomalidomide, cyclophosphamide, dexamethasone in multiple myeloma (MM), sponsored by Fundación para la Investigación Biomédica de Córdoba. Started Feb 2016; status: terminated.
02
Drugs
pomalidomidecyclophosphamidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2015-004530-94.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004530-94.